ClinicalTrials.gg
RecruitingNCT05534009Updated Sep 19, 2025

Health Care Workers Cohort Study in the EuCARE Project (EuCARE-HCW)

An observational study in COVID-19, sponsored by Euresist Network GEIE. Recruiting at 7 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-19.

Sponsored by Euresist Network GEIE · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Apr 2022; still recruiting 4 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
1,800
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 392 studies in COVID-19 with a site in Italy — 37 open to participants now, 46 under way, 7 of them phase 3. COVID-19 · Italy.

Planned enrollment
38th of 238
1,800 · median 251
Started
2022
with 35 others
Observational
238 of 392
24 open now
Primary completion
2025-12
later than 27 of 45 live
Registered
323rd of 392
by date

Among the 392 studies in COVID-19 with a site in Italy, this one is the 38th largest by planned enrollment of the 238 observational ones that give a count, is one of 36 that started in 2022, is one of 238 observational ones, reaches primary completion later than 27 of the 45 other live ones, and was the 323rd registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

37 of the 392 studies in COVID-19 with a site in Italy are open now. Recruiting first, the newest first:

31 more — sign in →

All 37 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 392 studies in COVID-19 with a site in Italy, or all of them as a file.
02

Study summary

The WP3 healthcare workers cohort in EuCARE is an observational multicentre study including collection of retrospective (historical) and prospective data and sample collection from health care workers with either a vaccination or a confirmed SARS-CoV-2 infection. Samples from HCW are sent to central laboratories for WP2 study were the impact of different variants in humoral and cellular immunity is to be analysed by biostatistical methods and with artificial intelligence in WP5. This analysis will focus on the impact on vaccine escape of viral variants / viral sequences as well as on any escape from any combination of natural and vaccine induced immunity. Eight countries will participate (Portugal, Italy, Germany, Lithuania, Georgia, Russia, Vietnam and Mexico).

Read the detailed description

Background: Protection from SARS-CoV-2 infection is known to occur soon after vaccination or natural disease, fading over time. Although protection from serious illness does occur, protection from infection is insufficient and the impact of each variant and of each vaccine or vaccine schedule is a matter of continuous study. Recruiting participants from countries with different vaccines and vaccine schedules is of upmost importance to analyse these relationships and breakthrough infections. Study objectives: The EuCARE-HCW study contributes with data and samples from

HCW to EuCARE-IMMUNITY study that will analyse the NtAb and CMI to different SARS- CoV-2 variants following any combination of natural infection and vaccination. Specific

objectives include:

  • to collect data and biological material from COVID-19 healthcare workers in 9 clinics from 8 countries and 3 continents.
  • Enrolment of HCW with an immunogenic event, either vaccination or infection.
  • Periodic collection of serum and whole blood every 4 months since enrolment and during 12-24 months (depending on how long immunity persists).
  • Sample preparation, storage and shipment to central EuCARE laboratories where WP2 study group will analyse natural and artificial immunity to SARS-CoV-2 variants (EuCARE-IMMUNITY), namely:

    • Analyse the magnitude, breadth and duration of immunity following natural infection and/or vaccination.
    • Define the cross-immunity among the different viral variants.
    • Analyse the immune escape in a comprehensive set of combinations of vaccines and natural infection(s).
  • To accomplish the above objectives, WP2 will test:

    • Neutralising antibodies
    • Cellular immunity
    • Viral sequences
03

Conditions studied

  • COVID-19

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

For each subject baseline will be the occurrence of the first known immunization event, either natural infection or vaccination. The follow-up is planned to last 24 months with respect to this baseline.

Health CareWorkers can be enrolled in the category of:

(i) vaccination not followed by any later infection, (ii) infection followed by vaccination and (iii) vaccination followed by infection. However, infections diagnosed during the first wave of the epidemic are suitable for the analysis of natural immunity to SARS-CoV-2 because vaccination was administered several months later.

Eligibility criteria

Inclusion Criteria:

The study subjects will be selected based on the following inclusion criteria:

  1. Adult (>18 years) HCW with mandatory information on their SARS-CoV-2 infection and vaccination status.
  2. For those with a history of SARS-CoV-2 infection, diagnosis obtained by detection of SARS-CoV-2 RNA
  3. Having a signed when required by ethical approval

Exclusion Criteria: NONE

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
1,800 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Heath care workers (HCW)

    Adult (\>18 years) HCW with mandatory information on their SARS-CoV-2 infection and vaccination status. For those with a history of SARS-CoV-2 infection, diagnosis obtained by detection of SARS-CoV-2 RNA

    Other: Follow up of the first known immunization event

Interventions

  • OtherFollow up of the first known immunization event

    The baseline for enrolment into the study is defined by the occurrence of the first known immunization event, either natural infection or vaccination. The follow-up is planned to last 24 months with respect to this baseline. In subjects with natural infection, the viral variant must be determined for each prospective case by analysis of a nasopharyngeal swab obtained as soon as possible at diagnosis. For historical cases where the variant was not determined and a contemporary nasopharyngeal swab has not been stored, the viral variant may be inferred when a specific variant was dominating the geographic area according to official records available at local health agencies. However, the variant assignment will be labelled as putative, rather than proved. HCWs can be enrolled in the category of: (i) vaccination not followed by any later infection, (ii) infection followed by vaccination and (iii) vaccination followed by infection.

06

What researchers measure

Primary outcomes

  1. Number of HCW involved in the study

    To collect the higher possible number of data and biological materials from the HCWs of the participating Units

    Time frame: through study completion, an average of 3 years

07

Study locations

7 of 7 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The study is part of a project funded by the European Commission and the project agreement with theCommission affirms that the data and the results will be publi

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: AFTER THE STUDY END NO TIME LIMIT WAS FIXED

Access criteria: REQUEST TO THE STUDY COORDINATOR OR TO THE PROJECTPARTNERS

Data sharing details ↗ · eucareresearch.eu

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2022 (actual). Primary completion is estimated for Dec 2025, 44 months after the start.

Of 1,640 non-industry observational studies under COVID-19, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 30. This study's planned 44 months is above that.

Counting every sponsor, half of 1,774 studies reached it within 13 months; a quarter within 5 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2022
First posted
Sep 9, 2022
StartActual
Apr 1, 2022
Primary completionEst.
Dec 15, 2025
CompletionEst.
Dec 15, 2025
Last update
Sep 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05534009
Lead sponsor
Euresist Network GEIE
Collaborators
Centro Hospitalar Lisboa Ocidental, ASST Santi Paolo e Carlo, Bach Mai Hospital, Hospital Regional de Alta Especialidad "Dr. Juan Graham Casasus", Heinrich-Heine University, Duesseldorf, Istituto Europeo di Oncologia, Vilnius University Hospital Santaros Klinikos
Responsible party
Sponsor
First posted
Sep 9, 2022
Start date
Apr 1, 2022
Primary completion
Dec 15, 2025 (estimated)
Completion
Dec 15, 2025 (estimated)
Last update
Sep 19, 2025

Study contacts

FRANCESCA INCARDONA, DR
Contact
francesca.incardona@euresist.org
+393356112830
CRISTINA TOSCANO, DR
study chair · Centro Hospitalar de Lisboa Ocidental (CHLO)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion